


2-27-06

1 Feb 16 47

Attorney's Docket No.: 17080-002002/601B



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John R. McDonald et al.      Art Unit : 1647  
Serial No. : 09/360,242      Examiner : Robert S. Landsman  
Filed : July 22, 1999      Cust. No. : 20985  
Conf. No. : 3140  
Title : Methods And Compositions For Treating Secondary Tissue Damage And Other  
Inflammatory Conditions And Disorders

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Dear Sir:

Transmitted herewith are an Supplemental Information Disclosure Statement, Forms PTO-1449 (4 pages), copies of Foreign Office Actions (6 pages), and cited non U.S. patent references for filing in connection with the above-identified application. Because this Supplemental Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account No. 06-1050, as stated below:

- ☒ The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 17080-002002/601B  
**Address all correspondence to:**  
Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 740118608 US  
Date of Deposit February 24, 2006  
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie L. Seidman



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : John R. McDonald et al.                      Art Unit : 1647  
Serial No. : 09/360,242                                      Examiner : Robert S. Landsman  
Filed : July 22, 1999                                        Cust. No. : 20985  
Conf. No. : 3140  
Title : METHODS AND COMPOSITIONS FOR TREATING SECONDARY  
         TISSUE DAMAGE AND OTHER INFLAMMATORY CONDITIONS AND  
         DISORDERS

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98**

This Supplemental Information Disclosure Statement is filed following a Request for Continued Examination of the above-captioned application and prior to receipt of an Office Action. Thus, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (4 pages) and copies of the cited non U.S. Patent documents are provided herewith.

The documents cited on the Forms PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"  
"Express Mail" Mailing Label Number EV 740118608 US  
Date of Deposit February 24, 2006  
I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.


Stephanie L. Seidman

The Applicant also makes known to the Examiner, Foreign Office Actions received for the corresponding Foreign applications. The corresponding Foreign applications and the communications provided are listed below.

<u>Foreign Appln. No.</u>	<u>Country</u>	<u>Attorney Dkt No.</u>	<u>Status</u>	<u>Foreign Communications</u>
PCT/CA99/00659	PCT	002WO1	National	ISR, IPER
48918/99	Australia	002AU1	Abandoned	1 <sup>st</sup> Exam report
2004202331	Australia	002AU2	Pending	1 <sup>st</sup> Exam report
2,335,105	Canada	002CA1	Pending	1 <sup>st</sup> Exam report
99932572.3	European	002EP1	Granted	Communications under Article 96(2)EPC; Rule 51(4) EPC and Article 97(2) EPC
03076150.6	European	002EP2	Pending	Two Communications under 96(2) EPC

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.


Respectfully submitted,

  
Stephanie Seidman  
Reg. No. 33,779

Attorney Docket No. 17080-002002/601B

**Address all correspondence to:**

Stephanie L. Seidman  
Fish & Richardson P.C.  
12390 El Camino Real  
San Diego, California 92130  
Telephone: (858) 678-5070  
Facsimile: (202) 626-7796  
email: seidman@fr.com



Sheet 1 of 4

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17080-002002/601B	Application No. 09/360,242
	Applicant John R. McDonald et al.		
	Filing Date July 22, 1999	Group Art Unit 1647	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AA	Adamus et al., "Similar pattern of MCP-1 expression in spinal cords and eyes of Lewis rats with experimental autoimmune encephalomyelitis associated anterior uveitis," Journal of Neuroscience Research 50: 531-538 (1997)
	AB	Amerio et al., "Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications," Current Drug Targets – Inflammation & Allergy 2(1): 81-94 (2003)
	AC	Badolato et al., "Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes," Blood 90(7): 2804-2809 (1997)
	AD	Baggiolini, M., "Chemokines in pathology and medicine," Journal of Internal Medicine 250: 91-104 (2001)
	AE	Barnes et al., "Polyclonal antibody directed against human RANTES ameliorates disease in the Lewis rat adjuvant-induced arthritis model," J. Clin. Invest. 101(12): 2910-2919 (1998)
	AF	Batra, "Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells," Journal Of Biological Chemistry 265(25): 15198-15202 (1990)
	AG	Boring et al., "Molecular cloning and functional expression of murine JE (monocyte chemoattractant protein 1) and murine macrophage inflammatory protein 1alpha receptors: evidence for two closely linked C-C chemokine receptors on chromosome 9," The Journal of Biological Chemistry 271(13): 7551-7558 (1996)
	AH	Boring et al., "Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice," J Clin Invest 100: 2552-2561 (1997)
	AI	Braman, S.S. and F.J. Martinez, "COPD: Awareness, early diagnosis, and intervention CME/CE," Live Web Conference, November 17, 2005, <a href="http://www.medscape.com">www.medscape.com</a> , 31 pages
	AJ	Chan et al., "Reactivity of murine cytokine fusion toxin, diphtheria toxin <sub>390</sub> -murine interleukin-3 (DT <sub>390</sub> -mIL-3), with bone marrow progenitor cells," Blood 88: 1445-1456 (1996)
	AK	Charo, I.F. and M.B. Taubman, "Chemokines in the pathogenesis of vascular disease," Circulation Research 95: 858-866 (2004)
	AL	Chiang et al., "Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice," J. Clin. Invest. 97(6): 1512-1524 (1996)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17080-002002/601B	Application No. 09/360,242
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant John R. McDonald et al.	
		Filing Date July 22, 1999	Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AM	Couser et al., "Sensitized cells come of age: a new era in renal immunology with important therapeutic implications," J. Am Soc. Nephrol. 10: 664-665 (1999)
	AN	De Klerck et al., "Pro-inflammatory properties of stromal cell-derived factor-1 (CXCL12) in collagen-induced arthritis," Arthritis Research & Therapy 7: R1208-R1220 (2005)
	AO	Debinski et al., "Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin," Clinical Cancer Research 1: 1253-1258 (1995)
	AP	Frankel et al., "Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor," Protein Engineering 9(10): 913-919 (1996)
	AQ	Fryer et al., "Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperactivity and M2 receptor dysfunction," The Journal of Clinical Investigation 116(1): 228-236 (2006)
	AR	Fujinaka et al., "Suppression of anti-glomerular basement membrane nephritis by administration of anti-monocyte chemoattractant protein-1 antibody in WKY rats," J Am Soc Nephrol 8: 1174-1178 (1997)
	AS	Hu et al., "Depletion of T lymphocytes with immunotoxin retards the progress of experimental allergic encephalomyelitis in rhesus monkeys," Cellular Immunology 177: 26-34 (1997)
	AT	Hur et al., "Macrophage Activation Syndrome in a Child with Systemic Juvenile Rheumatoid Arthritis," J Korean Med Sci 20: 695-8 (2005)
	AU	Hvas et al., "Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions," Scand. J. Immunol. 46: 195-203 (1997)
	AV	Johnson et al., "Chemokine inhibition – why, when, where, which, and how?" Biochemical Society Transactions 32(2): 366-377 (2004)
	AW	Kaartinen et al., "Extracellular mast cell granules carry apolipoprotein B-100-containing lipoproteins into phagocytes in human arterial intima. Functional coupling of exocytosis and phagocytosis in neighboring cells," Arteriosclerosis, thrombosis, and vascular biology 15: 2047-2054 (1995)
	AX	Kaartinen et al., "Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF- $\alpha$ ," Circulation 94: 2787-2792 (1996)
	AY	Kaikita et al., "Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction," American Journal of Pathology 165(2): 439-447 (2004)
	AZ	Kreitman, R.J. and I. Pastan, "Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells," Blood 90(1): 252-259 (1997)
	BA	Lavaud et al., "Early influx of glomerular macrophages precedes glomerulosclerosis in the obese Zucker rat model," J Am Soc Nephrol 7(12): 2604-2615 (1996)
	BB	Leek et al., "Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma," Cancer Research 56: 4625-4629 (1996)
	BC	Linton et al., "Proatherogenic Role for NK Cells Revealed," Arterioscler Thromb Vasc Biol 24: 992-994 (2003)
	BD	Makita et al., "Effect of anti-macrophage migration inhibitory factor antibody on lipopolysaccharide-induced pulmonary neutrophil accumulation," Am J Respir Crit Care Med 158: 573-579 (1998)
	BE	Mansfield et al., "Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors," Blood 90(5): 2020-2026 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17080-002002/601B	Application No. 09/360,242
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant John R. McDonald et al.	
		Filing Date July 22, 1999	Group Art Unit 1647

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	BF	Matsumoto et al., "Common T cell receptor clonotype in lacrimal glands and labial salivary glands from patients with Sjögren's syndrome," J Clin Invest 97(8): 1969-1977 (1996)
	BG	Matsumura et al., "Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxicity," J Clin Invest 97(10): 2192-2203 (1996)
	BH	Metcalfe et al., "Mast Cells," Physiological Reviews 77(4): 1033-1079 (1997)
	BI	Middleton et al., "Leukocyte extravasation: chemokine transport and presentation by the endothelium," Blood 100(12): 3853-3860 (2002)
	BJ	Mörner et al., "Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage," Journal of Virology 73(3): 2343-2349 (1999)
	BK	Moser, B. and P. Loetscher, "Lymphocyte traffic control by chemokines," Nature Immunology 2(2): 123-128 (2001)
	BL	Murdoch et al., "Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues," Blood 104(8): 2224-2234 (2004)
	BM	Ofulue et al., "Time course of neutrophil and macrophage elastolytic activities in cigarette smoke-induced emphysema," Am J Physiol 275(6 Pt 1): L1134-44 (1998)
	BN	Ogata et al., "The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats," Journal of Pathology 182: 106-114 (1997)
	BO	Pawluczyk, I.Z. and K.P.G. Harris, "Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis," J Am Soc Nephrol 8: 1525-1536 (1997)
	BP	Qin et al., "The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions," J Clin Invest 101: 746-754 (1998)
	BQ	Rastaldi et al., "Adhesion molecules expression in nonrescending acute post-streptococcal glomerulonephritis," J Am Soc Nephrol 7: 2419-2427 (1996)
	BR	Rep et al., "Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans," J Clin Invest 99(9): 2225-31 (1997)
	BS	Sakane et al., "Etiopathology of Behcet's Disease Immunological Aspects," Yonsei Medical Journal 38(6): 350-358 (1997)
	BT	Sallusto et al., "Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells," Science 277: 2005-2007 (1997)
	BU	Sansores et al., "Effect of exposure of guinea pigs to cigarette smoke on elastolytic activity of pulmonary macrophages," CHEST 112: 214-219 (1997)
	BV	Schuh et al., "Intrapulmonary targeting of RANTES/CCL5-responsive cells prevents chronic fungal asthma," Eur J Immunol 33: 3080-3090 (2003)
	BW	Shapiro, S.D., "The Macrophage in Chronic Obstructive Pulmonary Disease," Am J Respir Crit Care Med 160: S29-S32 (1999)
	BX	Speyer et al., "Novel chemokine responsiveness and mobilization of neutrophils during sepsis," American Journal of Pathology 165(6): 2187-2196 (2004)
	BY	Stout, R.D. and J. Suttles, "T Cell Signaling of Macrophage Function in Inflammatory Disease," Frontiers in Bioscience 2: d197-206 (May 1, 1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17080-002002/601B	Application No. 09/360,242
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant John R. McDonald et al.	
		Filing Date July 22, 1999	Group Art Unit 1647

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BZ	Takada et al., "Increased serum levels of interferon-gamma-inducible protein 10 and monokine induced by gamma interferon in patients with haemophagocytic lymphohistiocytosis," Clin Exp Immunol 133: 448-453 (2003)
	CA	Tangirala et al., "Regulation of expression of the human monocyte chemotactic protein-1 receptor (hCCR2) by cytokines," Journal of Biological Chemistry 272(12): 8050-8056 (1997)
	CB	Teixeira et al., "Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin," J Clin Invest 100: 1657-1666 (1997)
	CC	Tetley, T.D., "Macrophages and the Pathogenesis of COPD," CHEST 121: 156S-159S (2002)
	CD	Tran et al., "Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice," Journal of Immunology 161: 3767-3775 (1998)
	CE	Vallera et al., "Anti-graft-versus-host disease effect of DT <sub>390</sub> -anti-CD3sFv, a single-chain Fv fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T-cell receptor," Blood 88(6): 2342-2353 (1996)
	CF	Vallera et al., "Renal dysfunction accounts for the dose limiting toxicity of DT <sub>390</sub> anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin," Protein Engineering 10(9): 1071-1076 (1997)
	CG	Wada et al., "Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1)," FASEB J 10: 1418-1425 (1996)
	CH	Weisberg et al., "CCR2 modulates inflammatory and metabolic effects of high-fat feeding," The Journal of Clinical Investigation 116(1): 115-124 (2006)
	CI	Xu et al., "Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance," J Clin Invest 112: 1821-1830 (2003)
	CJ	Youngs et al., "Chemokines induce migrational responses in human breast carcinoma cell lines," Int J Cancer 71: 257-266 (1997)
	CK	Zoja et al., "Renal expression of monocyte chemoattractant protein-1 in lupus autoimmune mice," J Am Soc Nephrol 8: 720-729 (1997)
	CL	Zwacka et al., "CD4 <sup>+</sup> T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver," J Clin Invest 100(2): 279-289 (1997)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	